IP Library › Granted Patent US 12,589,083
Granted Patent B2
US 12,589,083 · App. 17/523,193 · Granted Mar 31, 2026

Abuse-deterrent dosage forms containing esketamine

Inventors: Derek Moe (Mound, MN); Randal Seburg (Louisville, KY); Sagar Rane (Bellevue, WA)
Assignee: CLEXIO BIOSCIENCES LTD.
A61K31/135A61K9/2009A61K9/2013A61K9/2018A61K9/2027A61K9/2054G01N2030/027
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,589,083
App. No.
17/523,193
Granted
Mar 31, 2026
Kind
B2
Abstract

Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.

Claims (14)

1 . A method of treating depression comprising orally administering to a subject in need thereof, an immediate release tablet comprising esketamine or a pharmaceutically acceptable salt thereof, sodium bicarbonate in an amount of no more than 2.2 wt % and 2-(2-chlorophenyl)-2-(methylamino)-6-methylidenecyclohexan-1-one in an amount that is no more than 5.5 wt % after storage in accelerated conditions for at least 6 months.

2 . The method of claim 1 , wherein the immediate release tablet comprises between 5 and 100 mg of esketamine or a pharmaceutically acceptable salt thereof.

3 . The method of claim 1 , wherein the immediate release tablet comprises 40 mg base equivalent of esketamine.

4 . The method of claim 1 , wherein the immediate release tablet comprises between 20 mg and 100 mg of esketamine.

5 . The method of claim 4 , wherein prior to the administration, the immediate release tablet has been exposed to a storage period of six months;

after the storage period, the area under a peak corresponding to 2-(2-chlorophenyl)-2-(methylamino)-6-methylidenecyclohexan-1-one present in the tablet is measured by high performance liquid chromatography (HPLC); and

the total amount of 2-(2-chlorophenyl)-2-(methylamino)-6-methylidenecyclohexan-1-one present in the tablet is determined to be no more than 5.5 wt. %;

wherein the peak corresponding to 2-(2-chlorophenyl)-2-(methylamino)-6-methylidenecyclohexan-1-one appears at a relative retention time of about 1.3 minutes when using C18, 100×3.0 mm, 3.5 μm HPLC column at a temperature of 45° C. and a sample temperature of 4° C., with a mobile phase comprising 0.050% trifluoroacetic acid (TFA) in water and 0.0025% TFA in acetonitrile and UV detection at 215 nm.

6 . The method of claim 5 , wherein the tablet is exposed to 40° C.±2° C. and 75%±5% relative humidity for the six month storage period.

7 . The method of claim 5 , wherein the tablet comprises 40-60 mg of esketamine.

8 . The method of claim 5 , wherein the tablet comprises 60 mg of esketamine.

9 . The method of claim 5 , wherein the 2-(2-chlorophenyl)-2-(methylamino)-6-methylidenecyclohexan-1-one is measured in an amount of no more than 0.2 wt % after the storage period.

10 . The method of claim 5 , wherein the 2-(2-chlorophenyl)-2-(methylamino)-6-methylidenecyclohexan-1-one is measured in a non-detectable amount after the storage period.

11 . The method according to claim 1 , wherein the immediate release tablet comprises sodium bicarbonate in an amount of no more than 2 wt %.

Continuity (3)
Division 16869309 · May 7, 2020
Provisional Application 62844286 · May 7, 2019
Related Publication 20220062200A1 · Mar 3, 2022
References Cited (190)
US 2798053A · Brown · 1957 [cited by applicant]
US 2909462A · Warfield et al. · 1959 [cited by applicant]
US 5169645A · Shukla et al. · 1992 [cited by applicant]
US 5248669A · Amer · 1993 [cited by applicant]
US 5472712A · Oshlack et al. · 1995 [cited by applicant]
US 5500227A · Oshlack et al. · 1996 [cited by applicant]
US 5958459A · Chasin et al. · 1999 [cited by applicant]
US 5965161A · Oshlack et al. · 1999 [cited by applicant]
US 5968551A · Oshlack et al. · 1999 [cited by applicant]
US 6024981A · Khankari et al. · 2000 [cited by applicant]
US 6033686A · Seth · 2000 [cited by applicant]
US 6103261A · Chasin et al. · 2000 [cited by applicant]
US 6129933A · Oshlack et al. · 2000 [cited by applicant]
US 6143353A · Oshlack et al. · 2000 [cited by applicant]
US 6159501A · Skinhoj · 2000 [cited by applicant]
US 6245351B1 · Nara et al. · 2001 [cited by applicant]
US 6251430B1 · Zhang et al. · 2001 [cited by applicant]
US 6261599B1 · Oshlack et al. · 2001 [cited by applicant]
US 6290990B1 · Grabowski et al. · 2001 [cited by applicant]
US 6294195B1 · Oshlack et al. · 2001 [cited by applicant]
US 6309668B1 · Bastin et al. · 2001 [cited by applicant]
US 6316031B1 · Oshlack et al. · 2001 [cited by applicant]
US 6335033B2 · Oshlack et al. · 2002 [cited by applicant]
US 6375987B1 · Farah et al. · 2002 [cited by applicant]
US 6387404B2 · Oshlack et al. · 2002 [cited by applicant]
US 6399096B1 · Miller et al. · 2002 [cited by applicant]
US 6419954B1 · Chu et al. · 2002 [cited by applicant]
US 6500459B1 · Chhabra et al. · 2002 [cited by applicant]
US 6534091B1 · Garces et al. · 2003 [cited by applicant]
US 6572885B2 · Oshlack et al. · 2003 [cited by applicant]
US 6680071B1 · Johnson et al. · 2004 [cited by applicant]
US 6685964B1 · Bartholomaeus et al. · 2004 [cited by applicant]
US 6699502B1 · Fanara et al. · 2004 [cited by applicant]
US 6706281B2 · Oshlack et al. · 2004 [cited by applicant]
US 6708822B1 · Muni · 2004 [cited by applicant]
US 6730321B2 · Ting et al. · 2004 [cited by applicant]
US 6730325B2 · Devane et al. · 2004 [cited by applicant]
US 6733783B2 · Oshlack et al. · 2004 [cited by applicant]
US 6733790B1 · Garces Garces · 2004 [cited by applicant]
US 6743442B2 · Oshlack et al. · 2004 [cited by applicant]
US 6753014B1 · Sjoeblom · 2004 [cited by applicant]
US 6759059B1 · Pettersson et al. · 2004 [cited by applicant]
US 6780504B2 · Rupprecht et al. · 2004 [cited by applicant]
US 6793936B2 · Devane et al. · 2004 [cited by applicant]
US 6855735B2 · Friedman · 2005 [cited by applicant]
US 6863901B2 · Hirsh et al. · 2005 [cited by applicant]
US 6902742B2 · Devane et al. · 2005 [cited by applicant]
US 6905709B2 · Oshlack et al. · 2005 [cited by applicant]
US 7022313B2 · O'Connor et al. · 2006 [cited by applicant]
US 7090867B2 · Odidi et al. · 2006 [cited by applicant]
US 7375083B2 · Mickle et al. · 2008 [cited by applicant]
US 7387792B2 · Hirsh et al. · 2008 [cited by applicant]
US 7399488B2 · Hirsh et al. · 2008 [cited by applicant]
US 7514100B2 · Oshlack et al. · 2009 [cited by applicant]
US 7658939B2 · Oshlack et al. · 2010 [cited by applicant]
US 7682633B2 · Matthews et al. · 2010 [cited by applicant]
US 7776314B2 · Bartholomaeus et al. · 2010 [cited by applicant]
US 8187636B2 · Soscia et al. · 2012 [cited by applicant]
US 8309060B2 · Bartholomaus et al. · 2012 [cited by applicant]
US 8349362B2 · Soscia et al. · 2013 [cited by applicant]
US 8445018B2 · Habib et al. · 2013 [cited by applicant]
US 8465776B2 · Hoarau · 2013 [cited by applicant]
US 8603525B2 · Oury et al. · 2013 [cited by applicant]
US 8637540B2 · Kumar et al. · 2014 [cited by applicant]
US 8647669B2 · Soscia et al. · 2014 [cited by applicant]
US 9707224B2 · Haswani et al. · 2017 [cited by applicant]
US 9757371B2 · Haswani et al. · 2017 [cited by applicant]
US 9827204B2 · Haswani et al. · 2017 [cited by applicant]
US 9913803B2 · Nivorozhkin et al. · 2018 [cited by applicant]
US 10034832B2 · Salce et al. · 2018 [cited by applicant]
US 10172810B2 · Mccarty · 2019 [cited by applicant]
US 10201505B2 · Haswani et al. · 2019 [cited by applicant]
US 10252982B2 · Nivorozhkin et al. · 2019 [cited by applicant]
US 10335379B2 · Manthei et al. · 2019 [cited by applicant]
US 10441544B2 · Glue et al. · 2019 [cited by applicant]
US 10568881B2 · Haswani et al. · 2020 [cited by applicant]
US 10888528B2 · Haswani · 2021 [cited by examiner]
US 11207318B2 · Haswani et al. · 2021 [cited by applicant]
US 11324707B2 · Moe et al. · 2022 [cited by applicant]
US 11534409B2 · Haswani · 2022 [cited by examiner]
US 11730702B2 · Haswani · 2023 [cited by examiner]
US 12268658B2 · Schumann · 2025 [cited by examiner]
US 20020006919A1 · Thosar et al. · 2002 [cited by applicant]
US 20020044966A1 · Bartholomaeus et al. · 2002 [cited by applicant]
US 20020110595A1 · Chang et al. · 2002 [cited by applicant]
US 20030065002A1 · Caruso et al. · 2003 [cited by applicant]
US 20030068375A1 · Wright et al. · 2003 [cited by applicant]
US 20030077297A1 · Chen et al. · 2003 [cited by applicant]
US 20030125347A1 · Anderson et al. · 2003 [cited by applicant]
US 20030180362A1 · Park et al. · 2003 [cited by applicant]
US 20030190358A1 · Oshlack et al. · 2003 [cited by applicant]
US 20040009219A1 · Odidi et al. · 2004 [cited by applicant]
US 20040028735A1 · Kositprapa · 2004 [cited by applicant]
US 20040052844A1 · Hsiao et al. · 2004 [cited by applicant]
US 20040092531A1 · Chizh et al. · 2004 [cited by applicant]
US 20040096499A1 · Vaya et al. · 2004 [cited by applicant]
US 20040096500A1 · Oshlack et al. · 2004 [cited by applicant]
US 20040105887A1 · Oshlack et al. · 2004 [cited by applicant]
US 20040121001A1 · Oshlack et al. · 2004 [cited by applicant]
US 20040131552A1 · Boehm · 2004 [cited by applicant]
US 20040170680A1 · Oshlack et al. · 2004 [cited by applicant]
US 20040185098A1 · Oshlack et al. · 2004 [cited by applicant]
US 20040253310A1 · Fischer et al. · 2004 [cited by applicant]
US 20050020613A1 · Boehm et al. · 2005 [cited by applicant]
US 20050074493A1 · Mehta et al. · 2005 [cited by applicant]
US 20050089568A1 · Oshlack et al. · 2005 [cited by applicant]
US 20050106249A1 · Hwang et al. · 2005 [cited by applicant]
US 20050163856A1 · Maloney et al. · 2005 [cited by applicant]
US 20050165038A1 · Gordon · 2005 [cited by applicant]
US 20050245483A1 · Brogmann et al. · 2005 [cited by applicant]
US 20060024361A1 · Odidi et al. · 2006 [cited by applicant]
US 20060104909A1 · Vaghefi et al. · 2006 [cited by applicant]
US 20060251721A1 · Cruz et al. · 2006 [cited by applicant]
US 20070009589A1 · Raghupathi et al. · 2007 [cited by applicant]
US 20070203165A1 · Shafer et al. · 2007 [cited by applicant]
US 20080069891A1 · Habib et al. · 2008 [cited by applicant]
US 20080311205A1 · Habib et al. · 2008 [cited by applicant]
US 20090022798A1 · Rosenberg et al. · 2009 [cited by applicant]
US 20090202634A1 · Jans et al. · 2009 [cited by applicant]
US 20090238868A1 · Mehta · 2009 [cited by applicant]
US 20090297617A1 · Rariy et al. · 2009 [cited by applicant]
US 20090304793A1 · Boehm · 2009 [cited by applicant]
US 20090317355A1 · Roth et al. · 2009 [cited by applicant]
US 20100015223A1 · Cailly-Dufestel et al. · 2010 [cited by applicant]
US 20100055133A1 · Duffield et al. · 2010 [cited by applicant]
US 20100098771A1 · Mehta · 2010 [cited by applicant]
US 20100099696A1 · Soscia et al. · 2010 [cited by applicant]
US 20110002985A1 · Shah et al. · 2011 [cited by applicant]
US 20120164228A1 · Suplie et al. · 2012 [cited by applicant]
US 20120202838A1 · Ghosh et al. · 2012 [cited by applicant]
US 20120321716A1 · Vachon et al. · 2012 [cited by applicant]
US 20130034503A1 · Howard et al. · 2013 [cited by applicant]
US 20140079740A1 · Salama · 2014 [cited by applicant]
US 20140093592A1 · Singh · 2014 [cited by examiner]
US 20140275276A1 · Basstanie · 2014 [cited by examiner]
US 20150030677A1 · Adjei et al. · 2015 [cited by applicant]
US 20150057304A1 · Thompson et al. · 2015 [cited by applicant]
US 20150118303A1 · Haswani et al. · 2015 [cited by applicant]
US 20150328168A1 · Daviaud-Venet et al. · 2015 [cited by applicant]
US 20160310418A1 · Fanda et al. · 2016 [cited by applicant]
US 20170143637A1 · Haswani et al. · 2017 [cited by applicant]
US 20170157052A1 · Haswani · 2017 [cited by examiner]
US 20170354654A1 · Sackler · 2017 [cited by applicant]
US 20180185354A1 · Haswani · 2018 [cited by examiner]
US 20180296501A1 · During · 2018 [cited by applicant]
US 20190380978A1 · Rands et al. · 2019 [cited by applicant]
US 20200121619A1 · Rey · 2020 [cited by applicant]
US 20200147005A1 · Kagan et al. · 2020 [cited by applicant]
EP 1103256A1 · 2001 [cited by applicant]
EP 1419766A1 · 2004 [cited by applicant]
EP 1504757A2 · 2005 [cited by applicant]
EP 1694724A1 · 2006 [cited by applicant]
EP 1782834A2 · 2007 [cited by applicant]
JP 2015511953 · 2015 [cited by applicant]
WO 9939698A1 · 1999 [cited by applicant]
WO 0180826A2 · 2001 [cited by applicant]
WO 0236099A1 · 2002 [cited by applicant]
WO 2002092059A1 · 2002 [cited by applicant]
WO 2004026256A2 · 2004 [cited by applicant]
WO 2004026262A2 · 2004 [cited by applicant]
WO 2004064807A1 · 2004 [cited by applicant]
WO 2004093819A2 · 2004 [cited by applicant]
WO 2005034930A1 · 2005 [cited by applicant]
WO 2007103293A2 · 2007 [cited by applicant]
WO 2008024490A2 · 2008 [cited by applicant]
WO 2008134071A1 · 2008 [cited by applicant]
WO 2009036812A1 · 2009 [cited by applicant]
WO 2009059701A2 · 2009 [cited by applicant]
WO 2010033195A1 · 2010 [cited by applicant]
WO 2013077851A1 · 2013 [cited by applicant]
WO 2013128276A2 · 2013 [cited by applicant]
WO 2014057351A1 · 2014 [cited by applicant]
WO 2015066172A1 · 2015 [cited by applicant]
WO 2015120201A1 · 2015 [cited by applicant]
WO 2016094358A1 · 2016 [cited by applicant]
WO 2017059374A1 · 2017 [cited by applicant]
WO 2020075134A1 · 2020 [cited by applicant]
Co-pending U.S. Appl. No. 17/523,193, filed Nov. 10, 2021. [cited by applicant]
Drug Discovery Trends Editor (DDT Editor) (Drug Discovery and Development, Testing Drug Stability for Long-Term Storage, Oct. 2012) (Year: 2012). [cited by applicant]
ICH Harmonised Tripartite Guideline (ICH) (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Feb. 2003, pp. 1-18) (Year: 2003). [cited by applicant]
Loh et al (Asian Journal of Pharmaceutical Sciences, 2015, vol. 10, pp. 255-27 4) (Year: 2015). [cited by applicant]
Yanagihara et al (Yakugaku Zasshi (Journal of the Pharmaceutical Society of Japan), 1999, vol. 119, pp. 980-987) (Year: 1999). [cited by applicant]
Bannwarth, B. “Will Abuse-Deterrent Formulations of Opioid Analgesics Be Successful In Achieving Their Purpose?” Drugs, 2012, vol. 72, pp. 1713-1723. [cited by applicant]
Esin et al., “Neuropathic cancer pain: What we are dealing with? How to manage it?”, OncoTargets and Therapy (2014), vol. 7, pp. 599-618. [cited by applicant]
Frohoff-Hulsmann et al., “Aqueous Ethyl Cellulose Dispersion Containing Plasticizers of Different Water Solubility and Hydroxypropyl Methyl-Cellulose as Coating Material for Diffusion Pellets II: Properties of Sprayed F… [cited by applicant]
Gustafsson et al., “Characterisation of Particle Properties and Compaction Behaviour of Hydroxypropyl Methylcellulose with Different Degrees of Methoxyl/Hydroxypropl Substitution”, Euro. J. of Pharmaceutical Sci. (1999)… [cited by applicant]
Hyppola et al.,“Evaluation of Physical Properties of Plasticized Ethyl Cellulose Films Cast From Ethanol Solution Part I”, Int'l J. of Pharma. (1996), vol. 133, pp. 161-170. [cited by applicant]
Siepmann et al., “A New Model Describing the Swelling and Drug Release Kinetics from Hydroxypropyl Methylcellulose Tablets”, J. of Pharma. Sci. (1999), vol. 88, No. 1, pp. 65-72. [cited by applicant]
Sung et al., “Effect of Formulation Variables on Drug and Polymer Release from HPMC-Based Matrix Tablets”, International Journal of Pharmaceutics (1996), vol. 142, pp. 53-60. [cited by applicant]
Viriden et al., “Investigation of Critical Polymer Properties for Polymer Release and Swelling of HPMC Matrix Tablets”, Euro. J. Pharma. Sci. (2009), vol. 36, pp. 297-309. [cited by applicant]